Walgreens, Qualcomm partner for connected health

Qualcomm Life is collaborating with Walgreens to power device connectivity with Walgreens mobile and web applications and its rewards program with robust medical device connectivity and care coordination capabilities.

Walgreens has more than 8,200 stores nationwide and 82 million Balance Rewards members, according to a release. The Walgreens applications and Qualcomm-enabled branded devices will be available to consumers in the first half of 2015. Compatible Walgreens devices include a wrist-worn blood pressure cuff, a traditional blood pressure cuff and a blood glucose meter.

Within the apps, Qualcomm Life’s 2net Platform also will enable remote patient monitoring, transitional care support and chronic care management through a secure and seamless transmission of biometric data from patients’ connected medical devices.

Walgreens' reward members earn points for participating in various health-related programs and tracking progress toward a goal. With medical device connectivity powered by Qualcomm Life, Balance Rewards for healthy choices members can sync select mHealth devices directly to their Balance Rewards account, earning points and enabling pharmacists to electronically access biometrics and health status information.

“Whether transitioning from a hospital to the home or managing a chronic condition such as heart disease or diabetes, Walgreens connectivity solution powered by Qualcomm Life will allow us to help our customers achieve improved health through regular biometric communication with their providers,” said Adam Pellegrini, Walgreens divisional vice president of digital health, in the release.

“Additionally, Qualcomm Life’s platforms help us to reward participating customers for their choice to become more informed and engaged in their healthcare.”

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.